Paraza Pharma, a Canada-based, fully integrated drug discovery organisation, announced on Monday that it has named Dr Chudi Ndubaku as its new chief scientific officer.
In the new role, Dr Ndubaku is to head and drive the strategic growth of the company's R&D division, with unitary focus to further improve the scientific impact of Paraza research on client-partners' programs.
Dr Ndubaku has held various senior scientific leadership positions at Genentech, Aduro Biotech and ORIC Pharmaceuticals.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval